Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 4/20 | 0.45 |
| ▸ | CDK8 | P49336 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578631 | 0.88 | ALDH1A1 (0.59) | ALDH1A1TSHRPOLBLMNAKMT2A | |
| SCHEMBL4581407 | 0.83 | HSD17B10 (0.54) | ALDH1A1TSHRPOLBLMNAKMT2A | |
| SCHEMBL5267766 | 0.82 | CCNC (0.61) | CCNCCDK8 | |
| SCHEMBL4580445 | 0.80 | PRKAA2 (0.52) | ALDH1A1TSHRKMT2AMEN1CCNC | |
| SCHEMBL5263350 | 0.80 | CCNC (0.64) | CCNCCDK8 | |
| SCHEMBL4580344 | 0.79 | CCNC (0.50) | CCNCCDK8SCN9A | |
| SCHEMBL4580362 | 0.76 | CCNC (0.49) | ALDH1A1TSHRLMNAKMT2ACYP3A4 | |
| SCHEMBL4580748 | 0.74 | CCNC (0.45) | ALDH1A1LMNACCNCCDK8 | |
| SCHEMBL4580301 | 0.74 | CCNC (0.56) | CCNCCDK8SCN9A | |
| SCHEMBL4578993 | 0.73 | CCNC (0.54) | KMT2ACYP3A4CCNCCDK8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | claimed |
| EP-2922540-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. Hoffmann-La Roche AG (CH) | 2015-09-30 | — | — | EP | claimed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | claimed |
| WO-2014079787-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | claimed |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| EP-1773834-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | Serenex, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006017672-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | SERENEX INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657014-B2 | Substituted 1,6-naphthyridines | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2922540-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. Hoffmann-La Roche AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-10 | — | — | US | disclosed |
| WO-2014079787-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014079787-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
| EP-1773834-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | Serenex, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006017672-A2 | 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES | SERENEX INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | ALDH1A1 107/4885TSHR 1236/4885POLB 2026/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | ALDH1A1 107/4885TSHR 1236/4885POLB 2026/4885 |
| US-20150252044-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINES | CBR3, CBR1, NR2C2 | ALDH1A1 1072/4885TSHR 113/4885POLB 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.